Urgent Angiography Indication Assessment Tool in NSTE ACS

Clinical calculation support · Verify results before clinical use

Clinical urgency assessment

Select Yes or No for each feature. This is a triage aid, not a validated numerical risk score.

7Features

Refractory or recurrent chest pain at rest

Persistent or recurrent ischemic symptoms despite optimal medical therapy.

Very high risk

Hemodynamic instability or cardiogenic shock

For example, sustained hypotension, need for vasoactive support, or peripheral hypoperfusion.

Very high risk

Electrical instability

For example, sustained VT/VF or resuscitated cardiac arrest suspected to be ischemic.

Very high risk

Acute pulmonary edema or heart failure related to ischemia

New or worsening heart failure in the context of suspected NSTE-ACS.

Very high risk

Worsening ischemic mitral regurgitation or suspected mechanical complication

For example, a new/worsening systolic murmur with shock or pulmonary edema.

Very high risk

Ongoing or recurrent dynamic ST-segment changes

Dynamic ECG changes consistent with myocardial ischemia; exclude STEMI or an occlusion equivalent.

High risk

Steep rise in serial cardiac troponin despite optimized therapy

A convincing steep rise on serial measurements in the appropriate clinical context.

High risk
Reset assessment

Clinical interpretation

This tool separates features that support an immediate invasive strategy from selected high-risk findings that generally support early angiography. It does not calculate a validated score and should only be used in the context of a working diagnosis of NSTE-ACS.

Immediate invasive strategy

  • Refractory or recurrent ischemic chest pain despite optimal medical therapy.
  • Hemodynamic instability or cardiogenic shock.
  • Electrical instability, including sustained ventricular arrhythmia.
  • Acute pulmonary edema or heart failure related to ischemia.
  • Worsening ischemic mitral regurgitation or suspected mechanical complication.

High-risk findings that support early angiography

  • Ongoing dynamic ST-segment changes consistent with ischemia.
  • A steep rise in serial troponin values despite optimized medical therapy.
  • Integrate these findings with GRACE risk, serial ECG/troponin results, bleeding risk, comorbidities, and patient preference.

References

Rao SV, O'Donoghue ML, Ruel M, et al.2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2025.doi:10.1016/j.jacc.2024.11.009
Byrne RA, Rossello X, Coughlan JJ, et al.2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826.doi:10.1093/eurheartj/ehad191
Mehta SR, Granger CB, Boden WE, et al.Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165–2175.doi:10.1056/NEJMoa0807986
Jobs A, Mehta SR, Montalescot G, et al.Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. Lancet. 2017;390:737–746.doi:10.1016/S0140-6736(17)31490-3
Clinical disclaimer: This decision-support tool is intended for qualified healthcare professionals and does not replace clinical judgment, local ACS protocols, cardiology consultation, or emergency transfer pathways. It is not intended for patients with clear STEMI, in whom the appropriate reperfusion pathway must proceed without delay. Consider procedural risks, renal function, bleeding risk, goals of care, and patient preferences without delaying life-saving treatment in an unstable patient.